Kinisoquin for preventing blood clots in pancreatic cancer
Part of Cancer, Digestive system, Heart & circulation, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests whether an investigational drug called Kinisoquin™ can help prevent blood clots in people with advanced pancreatic cancer who are starting their first chemotherapy. It may be a good option if you are looking for extra protection against clots during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic (spread) or locally advanced (cannot be removed) pancreatic cancer.
- You are about to start your first chemotherapy for this cancer (either newly diagnosed or after a recurrence).
- You are 18 years or older.
- You do not have a high risk of bleeding or a recent blood clot (within 12 months).
- You are not taking blood thinners, daily high-dose aspirin, or other anti-clotting drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
This trial tests an experimental drug for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.